跳至主要内容
临床试验/NCT00476138
NCT00476138Unknown1 期

Functional Effects of Epigallocatechingallate on Retinal Function in Glaucoma

Catholic University of the Sacred Heart2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2006年11月最近更新:
适应症
相关药物

试验速览

阶段
1 期
入组人数
40
试验地点
2
主要终点
PERG

研究概览

简要总结

The present study attempts to evaluate the potential beneficial effects of a flavonoid, the epigallocatechingallate, on retinal ganglion cell function, evaluated by pattern electroretinogram, in subjects with ocular hypertension or early glaucoma.

详细描述

Twenty ocular hypertension and twenty early open angle glaucoma patients will be randomly divided into two groups: 1. placebo group [ocular hypertension, n = 10, early glaucoma (n=10)], taking an oral placebo in addition to standard beta-blocker treatment for ocular hypertension; 2. Treatment group [ocular hypertension, n = 10, early glaucoma (n=10)], taking Epigallocatechingallate oral treatment (200 mg/day) in addition to standard beta-blocker treatment for ocular hypertension. The patients will undergo standard clinical examination including automated Humphrey perimetry (30-2), pattern electroretinogram recording and measurement of retinal nerve fiber layer thickness by Optical Coherence Tomography (OCT stratus) at baseline, 3 and 6 months of treatment and follow-up. All patients will be again tested at 3 and 6 months after changing, in a cross-over design, placebo with drug assumption and vice versa.

Main outcome measure will be pattern electroretinogram amplitude. Secondary measures will be Humphrey perimetry mean deviation and corrected pattern standard deviation, and the thickness of optic nerve fibers measured by OCT.

Pattern Electroretinogram recordings.

Stimuli will be horizontal gratings of 1.6 cycles/degree spatial frequency, modulated in counterphase at 8.14 Hz and electronically generated on a high-resolution TV monitor (contrast: 70%; mean luminance: 80 cd/m2; field size: 31° [width] x 24° [height]). Subjects fixate at the center of the stimulating field with natural pupils, whose size will be measured, at a viewing distance of 57 cm. The subjects or patients will wear full refractive correction for the test distance. Signals will be recorded by a standard, flat-cup, 9 mm Ag/AgCl electrode taped on the skin of the lower eyelid. A similar electrode, placed over the eyelid of the contralateral, unstimulated eye, will be used as reference. Responses will be amplified (100, 000), bandpass filtered (1-30 Hz), sampled with a resolution of 12 bits and averaged (250 events) with automatic artifact rejection. Two replications will be obtained for each record to verify reproducibility. Peak-to-peak amplitude (in microV) of the Fourier analyzed response 2nd harmonic will be measured.

Retinal Nerve Fiber Thickness by OCT

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
Double

入排标准

年龄范围
35 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • IOP > 21 mmHg at the time of diagnosis
  • Response to ipotensive therapy
  • No visible alterations of the optical nerve head (if OHT)
  • Visual field: normal (if OHT), < -6dB at diagnosis (if POAG)
  • Alterations in PERG
  • Familiarity for glaucoma (if OHT)

排除标准

  • Change of ipotensive therapy
  • Ocular surgery
  • Other ocular pathologies

结局指标

主要结局

PERG

时间窗: six months

次要结局

  • Optical Coherence Tomography measurements of retinal nerve fiber layer thickness(six months)
  • IOP(six months)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验